Horizant^® significantly improved pain intensity score over the course of 14 weeks^1,11

The efficacy and tolerability of Horizant® were evaluated in a randomized, double-blind, placebo-controlled study in adults with PHN. Patients (N=376) were required to have a baseline 24-hour average pain score of ≥4 on an 11-point pain intensity numerical rating scale, ranging from 0 (no pain) to 10 (worst possible pain). Patients were excluded if, over the past year, they had certain psychiatric comorbidities, a history of drug or alcohol abuse, hepatic or renal impairment (creatinine clearance <60 mL/min or hemodialysis), abnormal electrocardiogram, uncontrolled hypertension, or a seizure disorder requiring medication.

The primary endpoint was change from baseline to end of maintenance treatment in mean 24-hour average pain intensity score. Additional endpoints included proportion of patients achieving a percent reduction in pain score from baseline and daytime/nighttime worst pain intensity.